United States ex rel. Lisitza v. Par Pharmaceutical Companies, Inc.

MEMORANDUM OPINION ÁND ORDER

JOHN J. THARP, Jr., United States District Judge

This case involves an alleged prescription-switching scheme in which defendant Par Pharmaceutical Companies allegedly caused pharmacies to submit false claims to avoid Medicaid reimbursement caps, resulting in overpayment by the federal and various state governments.1 The claims are brought as a qhi tarn action under the federal False Claims Act, 31 U.S.C. § 3729 et seq. (“FCA”), and parallel state statutes, by the relator Bernard Lisitza, various states,2 and the federal government, which has intervened with respect…